Haemonetics CorporationHAENYSE
Loading
Year-over-year research & development expense growth
Percentile
P46
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -4.61% |
| Q3 2025 | -8.54% |
| Q2 2025 | 2.18% |
| Q1 2025 | 0.54% |
| Q4 2024 | 11.95% |
| Q3 2024 | -2.15% |
| Q2 2024 | -40.92% |
| Q1 2024 | 84.37% |
| Q4 2023 | 4.74% |
| Q3 2023 | 0.13% |
| Q3 2023 | -47.61% |
| Q1 2023 | 90.28% |
| Q4 2022 | 16.46% |
| Q4 2022 | -0.06% |
| Q3 2022 | -49.55% |
| Q1 2022 | 115.30% |
| Q1 2022 | -7.52% |
| Q4 2021 | -14.55% |
| Q3 2021 | -31.87% |
| Q1 2021 | 148.54% |
| Q4 2020 | 10.91% |
| Q3 2020 | -12.74% |
| Q2 2020 | -54.87% |
| Q1 2020 | 145.34% |
| Q4 2019 | -5.69% |
| Q3 2019 | -0.87% |
| Q2 2019 | -14.40% |
| Q1 2019 | -2.57% |
| Q4 2018 | 4.60% |
| Q3 2018 | -8.75% |
| Q2 2018 | -15.16% |
| Q1 2018 | -10.78% |
| Q4 2017 | 65.23% |
| Q3 2017 | -8.20% |
| Q3 2017 | -56.93% |
| Q1 2017 | 124.78% |
| Q4 2016 | 1.51% |
| Q4 2016 | -27.11% |
| Q3 2016 | -48.13% |
| Q1 2016 | 101.51% |